Research programme: CCR5 antagonists - Novita Healthcare/TargetDrug

Drug Profile

Research programme: CCR5 antagonists - Novita Healthcare/TargetDrug

Alternative Names: CCR5 inhibitors - Novita Healthcare/TargetDrug

Latest Information Update: 24 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TargetDrug
  • Developer Novita Healthcare; TargetDrug
  • Class Small molecules
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 05 Aug 2009 Monogram Biosciences has been acquired by Laboratory Corporation of America Holdings
  • 04 Jun 2008 Avexa focusses resources previously assigned to this CCR5 antagonists programme to its HCV programme in collaboration with TargetDrug
  • 20 Apr 2007 Preclinical trials in prevention of HIV infections in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top